ClinicalTrials.gg
RecruitingNCT06421649PRONTOUpdated Nov 10, 2026

Investigating the Role of Adjuvant Proton Beam Therapy in Patients With Parotid Carcinoma

An interventional study of Proton Beam Therapy in Parotid Cancer, sponsored by The Christie NHS Foundation Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by The Christie NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 10, 2026Now RecruitingFirst site in United Kingdom+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Proton Beam Therapy (PBT) is an advanced radiotherapy technique. There are two National Health Service (NHS) PBT treatment centres in the UK, one in Manchester and one in London. The NHS is committed to ensuring the best use of this limited resource by investigating which patients will benefit from PBT treatment.

Evaluative Commissioning in Protons (ECIP) is a programme of studies that explore the role of PBT for patients with different types of cancer. They are funded by NHS England. ECIP studies are not randomised studies, which means that all eligible patients will be offered proton therapy. Any patient in the United Kingdom (UK) can be referred, and for patients that need to travel far to their nearest centre, accommodation will be available.

The main benefit of PBT, compared with photon radiotherapy, is the predicted reduction in radiation dose to surrounding healthy tissues. With photon radiotherapy, some radiation passes beyond the target area, affecting healthy tissues and causing side-effects. With PBT, the radiation dose stops within the target area, causing less damage to surrounding tissues, and limiting side effects.

PRONTO is a study within the ECIP programme exploring whether PBT can reduce treatment side effects for patients with salivary gland cancers who need radiotherapy following surgery. Whilst radiotherapy is associated with good cancer control, it commonly causes problematic side-effects such as loss of taste and dry mouth. These can be permanent and can negatively affect someone's quality of life. PRONTO's main aim is to see if PBT can reduce the loss of taste following radiotherapy.

Participants in PRONTO will be closely monitored by the medical team and with questionnaires. The patient experience will be compared to what we would expect with standard photon radiotherapy.

Read the detailed description

Malignant parotid tumours are uncommon. Whilst 85% of salivary gland tumours originate in the parotid gland, only 20-25% of these are malignant, representing only 3-6% of head and neck cancers. This is about 650 patients/year in the UK.

Standard treatment for local disease is with surgical resection followed by adjuvant radiotherapy for patients with high-risk features. Local control and 5-year survival rates are good, at >70% and >80% respectively, but radiotherapy is associated with considerable toxicity. More than 70% of patients receiving photon therapy experience significant dysgeusia (taste loss/alteration). This can be permanent, is associated with weight loss, diminished appetite, dry mouth, and negatively impact on Quality of Life (QoL).

The putative benefit of proton beam radiotherapy (PBT) relates to its characteristic deposition in the body, which limits the radiation dose received by surrounding healthy tissues. We hypothesise that irradiating the post-operative parotid bed with PBT rather than Intensity Modulated Radiation Therapy (IMRT), will reduce the dose delivered to the Organs at Risk (OAR), in particular the oral cavity (OC), leading to a reduction in acute and long term taste loss/alteration. The advantageous physical properties of PBT may also improve other side effects including fatigue, mucositis, nausea \& vomiting and potentially hearing problems, as well as overall QoL.

Radiotherapy planning studies:

Radiation planning studies have repeatedly shown statistically significant reductions in the dose delivered to healthy tissues including: the oral cavity, brainstem, spinal cord, contralateral parotid, ipsilateral and contralateral submandibular glands and ipsilateral temporal lobe. In particular, radiotherapy doses to the oral cavity are significantly reduced, typically to below 10 Gray (Gy). No routinely contoured OAR or region of interest was consistently found to have higher doses planning with protons, although skin dose may be higher.

Clinical Trials:

Whilst there are no randomised control trials comparing protons and photons for this cohort. However, there is some clinical evidence that the use of PBT leads to clinically meaningful improvements in the side effects experienced by patients. One study compared acute toxicities between matched groups receiving either protons or photons, demonstrating statistically significant reductions in dysgeusia, fatigue, mucositis and nausea and vomiting in patients undergoing proton treatment. In other studies, PBT is associated with very low toxicity level, such as less than 30% of patients experiencing any dysgeusia. This compares favourably to photon experience, such as in the phase 3 randomised controlled trial 'A Multicentre Randomised Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients with Parotid Tumours' (COSTAR) where approximately 60% of patients reported dysgeusia in the Head \& Neck 35 (HN35) questionnaire at 1 year. The PRONTO study is powered to identify a clinically meaningful reduction in taste dysfunction of at least 20%.

Whilst late toxicities are also likely under-reported in the retrospective international data, the published literature to date is very reassuring. The mean dose to the ipsilateral temporal lobe is reportedly reduced, and reflected in low levels of subsequent headache, fatigue and/or memory change. Similarly, whilst poorly captured, low levels of hearing dysfunction or otalgia have also been reported following PBT.

There is no rationale at all that cancer outcomes, either local control or overall survival, will be worse with PBT than photon treatment. In studies to date, local control (approximately 95%) and overall survival (89%-96%) has been excellent, and comparative to known photon experience.

02

Conditions studied

  • Parotid Cancer

Browse trials for

Keywords

  • proton beam therapy
  • protons
  • evaluative commissioning
03

In context

Parotid Neoplasms

28 studies on the registry are indexed under Parotid Neoplasms; 8 are open to participants now.

This study's planned enrollment of 97 is above the median of 50 across 19 interventional studies indexed under Parotid Neoplasms.

Browse Parotid Neoplasms studies →

Lead sponsor

The Christie NHS Foundation Trust is the lead sponsor of 100 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old.
  2. confirmed primary malignant tumours of parotid gland.
  3. Requiring post-operative radiotherapy to the parotid bed, with a dose equivalent of at least 60 Gray (Gy) in 2 Gy / fraction.
  4. Treatment delivered with radical intent.
  5. All patients must be suitable to attend regular follow-up, audiograms, toxicity monitoring, and be available for long term follow-up.
  6. Willingness to comply with the protocol, including travel to the proton centre for Intensity Modulated Proton Therapy (IMPT) treatment.
  7. Written .

Exclusion criteria

Exclusion Criteria:

  1. Previous radiotherapy to the head and neck region;
  2. Parotid tumours requiring primary radiation or those with gross residual disease;
  3. from squamous cell carcinoma of the head and neck to the parotid gland;
  4. Benign tumours requiring post operative radiotherapy;
  5. Previous or concurrent illness, which in the investigators opinion would interfere with either completion of therapy or follow-up;
  6. Patients requiring or receiving , concomitant or planned adjuvant chemotherapy.
  7. Patients who are eligible for PBT under routine commissioning
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (estimated)

Study arms

  • Experimental
    Proton Beam Therapy

    All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.

    Radiation: Proton Beam Therapy

Interventions

  • RadiationProton Beam Therapy

    All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.

06

What researchers measure

Primary outcomes

  1. Taste dysfunction

    Taste dysfunction as recorded on the European Organisation for the Research \& Treatment of Cancer (EORTC) Head \& Neck 43 (HN43) patient reported questionnaire. 43 questions with a Likert scale of 1 - 4 Higher score may mean a worse outcome

    Time frame: 12 months

Secondary outcomes

  1. Clinician reported acute and late toxicity using Common Terminology Criteria for Adverse Events (CTCAE) grades

    Using the CTCAE toxicity grade Grades 1 - 5 Higher score may mean a worse outcome

    Time frame: up to 24 months

  2. Clinician reported acute and late toxicity using Late Effects Normal Tissue - Subjective Objective Management Analytic (LENT-SOMA) scale

    Using the LENT-SOMA scale A multiple item scoring system composed of four domains; subjective, objective, management and analytic. Grades 0-4 Higher score may mean a worse outcome

    Time frame: up to 24 months

  3. Clinician reported acute and late toxicity - measurement of hearing changes

    Using pure tone audiometry to measure hearing changes Loss of hearing may mean a worse outcome

    Time frame: up to 24 months

  4. Patient reported acute and late toxicity using European Organisation for the Research & Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 module questionnaire

    Using the EORTC QLQ-C30 30 questions using a Likert scale of 1-4 Higher score may mean a worse outcome

    Time frame: up to 24 months

  5. Patient reported acute and late toxicity using European Organisation for the Research & Treatment of Cancer (EORTC) Head & Neck 43 (HN43) patient reported questionnaire.

    Using the EORTC HN43 patient reported questionnaire 43 questions using a Likert scale of 1-4 Higher score may mean a worse outcome

    Time frame: up to 24 months

  6. Patient reported acute and late toxicity using University of Washington Quality of Life (UW-QoL) questionnaire

    Using the UW-QoL questionnaire Most questions are scored on a Likert scale, 0=worst, 100=best Lower score may mean worse outcomes

    Time frame: up to 24 months

  7. Patient reported acute and late toxicity using Glasgow hearing Aid Benefit Profile (GHABP) questionnaire

    Using the GHABP questionnaire Possible values for response options (0=not applicable, 5=cannot manage at all) Higher score may mean worse outcomes

    Time frame: up to 24 months

  8. Loco-regional tumour control

    This will be measured as time to recurrence (measured in months from completion of treatment) and location of recurrence (within the primary nodal regional or distant spread)

    Time frame: up to 24 months

  9. Overall survival

    This will be measured in months from completion of treatment to death

    Time frame: up to 24 months

  10. Patient participation in the study each year

    Number of patients referred to and participating in the study annually

    Time frame: up to 24 months

  11. Study completion rates

    Review the number of patients completing radiotherapy and the number of patients completing follow up on the study as per protocol.

    Time frame: up to 24 months

  12. Oral cavity radiation dose

    Patients will be re-planned with photon radiotherapy, the dose distribution differences between the treatment proton plans and photon plans will be recorded in particular the dose to the oral cavity

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol. 2016 Feb;118(2):286-92. doi: 10.1016/j.radonc.2015.12.008. Epub 2016 Feb 8. PubMed 26867969 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Nov 2024 → Sep 2025, primary completion Jun 2028 → Sep 2029 and completion Jun 2029 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
May 20, 2024
StartActual
Sep 5, 2025was Nov 2024
Primary completionEst.
Sep 1, 2029was Jun 2028
CompletionEst.
Sep 1, 2029was Jun 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
2 sites added — first site in United Kingdom
Show 2 added (2 United Kingdom)
  • University College London Hospitals NHS Foundation Trust · London, United Kingdom
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
Nov 10, 2026
Start date
Nov 1, 2024→Sep 5, 2025 (actual)
Nov 10, 2026
Primary completion
Jun 1, 2028→Sep 1, 2029
Nov 10, 2026
Study completion
Jun 1, 2029→Sep 1, 2029
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United Kingdom
    Show 2 added (2 United Kingdom)
    • University College London Hospitals NHS Foundation Trust · London, United Kingdom
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    Start date Nov 1, 2024→Sep 5, 2025 (now actual)
    Primary completion Jun 1, 2028→Sep 1, 2029
    Study completion Jun 1, 2029→Sep 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06421649
Collaborators
Royal Marsden NHS Foundation Trust, University College London Hospitals
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Sep 5, 2025
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Romelie Rieu
Contact
romelie.rieu@nhs.net
0044 1619187172
Sally Falk
Contact
sally.falk@nhs.net
0044 1619187172
Chris Nutting
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion